H. Fujino

发表

Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy

M. Imamura, K. Chayama, D. Miki, 2017, Journal of Gastroenterology.

Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib

M. Imamura, K. Chayama, H. Aikata, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma

M. Imamura, K. Chayama, H. Aikata, 2021, Oncology.

Risk factors for histological progression of nonalcoholic steatohepatitis analyzed from repeated biopsy cases.

M. Imamura, K. Chayama, D. Miki, 2020, Journal of gastroenterology and hepatology.

Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease

M. Imamura, K. Chayama, T. Kawaguchi, 2021, Journal of Gastroenterology and Hepatology.

Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large‐scale, long‐term cohort study

M. Imamura, K. Chayama, D. Miki, 2016, Journal of gastroenterology and hepatology.

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment

M. Imamura, K. Chayama, D. Miki, 2022, PloS one.

Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib

M. Okada, M. Imamura, K. Chayama, 2021, Internal medicine.

Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma

M. Imamura, K. Chayama, D. Miki, 2020, Journal of gastroenterology and hepatology.

Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis.

Y. Yoshifuku, Tomohiro Miwata, H. Okanobu, 2010, Gastroenterologie clinique et biologique.

Signal activation of hepatitis B virus-related hepatocarcinogenesis by upregulation of SUV39h1.

M. Imamura, K. Chayama, D. Miki, 2020, The Journal of infectious diseases.

A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk

K. Awai, M. Imamura, K. Chayama, 2020, Clinical Journal of Gastroenterology.

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

M. Imamura, K. Chayama, H. Aikata, 2021, Cancers.

Incidence of microsatellite instability‐high hepatocellular carcinoma among Japanese patients and response to pembrolizumab

M. Imamura, K. Chayama, H. Aikata, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib

M. Imamura, K. Chayama, H. Aikata, 2020, Oncology.

Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study

M. Imamura, K. Chayama, D. Miki, 2021, BMC Gastroenterology.

Increase of non- HBV, non- HCV related hepatocellular carcinoma -Over 20 years single institution study-

M. Imamura, K. Chayama, D. Miki, 2020 .

Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus‐related cirrhosis

M. Imamura, K. Chayama, D. Miki, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Improvement of renal dysfunction in a patient with hepatitis C virus‐related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report

M. Imamura, N. Hiraga, K. Chayama, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report

M. Imamura, K. Chayama, K. Arihiro, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis

M. Imamura, N. Hiraga, K. Chayama, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

The effect of the skin–liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis

M. Imamura, D. Miki, H. Aikata, 2022, Journal of medical ultrasonics.

The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy

M. Imamura, K. Chayama, D. Miki, 2017, PloS one.

The impact of interferon‐free direct‐acting antivirals on clinical outcome after curative treatment for hepatitis C virus–associated hepatocellular carcinoma: Comparison with interferon‐based therapy

M. Imamura, K. Chayama, D. Miki, 2018, Journal of medical virology.

Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures

M. Imamura, K. Chayama, H. Aikata, 2020, Internal medicine.

Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

M. Imamura, K. Chayama, H. Ohdan, 2022, Journal of Gastroenterology.

Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients

M. Imamura, K. Chayama, H. Ohdan, 2021, Medicine.

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis

M. Imamura, K. Chayama, D. Miki, 2019, Hepatology communications.

Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg‐interferon, and ribavirin combination treatment for chronic hepatitis C

M. Imamura, N. Hiraga, K. Chayama, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety of sitagliptin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus.

M. Imamura, K. Chayama, H. Aikata, 2014, Hepato-gastroenterology.

Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection

M. Imamura, K. Chayama, H. Ohdan, 2022, Journal of Gastroenterology.

Clinical Outcomes of 2nd- and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma

M. Imamura, K. Chayama, H. Kohno, 2021, Oncology.

Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C

M. Imamura, N. Hiraga, K. Chayama, 2014, Journal of Gastroenterology.

CTL‐associated and NK cell‐associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients

M. Imamura, N. Hiraga, K. Chayama, 2018, Journal of viral hepatitis.

Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection—Pilot study

M. Imamura, K. Chayama, D. Miki, 2020, Journal of viral hepatitis.

A case with life-threatening secondary sclerosing cholangitis caused by nivolumab

M. Imamura, K. Chayama, N. Hattori, 2020, Clinical Journal of Gastroenterology.

The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma

M. Imamura, K. Chayama, K. Arihiro, 2022, International journal of cancer.

Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients

M. Imamura, K. Chayama, Shinji Tanaka, 2021, Journal of Infection.

Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis

M. Imamura, K. Chayama, D. Miki, 2020, Digestive Diseases and Sciences.

The effect of the skin–liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis

M. Imamura, D. Miki, H. Aikata, 2022, Journal of Medical Ultrasonics.

Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography

M. Imamura, D. Miki, H. Aikata, 2022, Journal of Medical Ultrasonics.

The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients

M. Imamura, K. Chayama, H. Aikata, 2017, Journal of Gastroenterology.

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab

M. Imamura, H. Ohdan, H. Aikata, 2021, Medicine.

Hepatitis B infection derived from a donor and de novo autoimmune hepatitis subsequent to pegylated-interferon treatment for recurrent hepatitis C after living-liver transplantation: A case report

M. Imamura, K. Chayama, H. Aikata, 2014 .

The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients

M. Imamura, K. Chayama, D. Miki, 2018, Antiviral therapy.

Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice

M. Imamura, N. Hiraga, K. Chayama, 2019, Journal of Gastroenterology.

Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy

M. Imamura, K. Chayama, D. Miki, 2020, Journal of medical virology.

Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.

K. Chayama, H. Ohdan, T. Fukuhara, 2015, Transplantation proceedings.

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

M. Imamura, K. Chayama, D. Miki, 2021, Journal of Experimental & Clinical Cancer Research.

Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy

M. Imamura, K. Chayama, H. Kohno, 2021, Oncology.

Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures

M. Imamura, K. Chayama, D. Miki, 2018, Journal of Gastroenterology.

Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma—Consideration of the Locations of Target Lesions

M. Imamura, Y. Nagata, S. Oka, 2023, Cancers.

A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion

M. Imamura, K. Chayama, H. Aikata, 2014, Clinical Journal of Gastroenterology.

Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib

M. Imamura, K. Chayama, D. Miki, 2020, Therapeutic advances in medical oncology.

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

M. Imamura, H. Kohno, H. Aikata, 2022, Cancers.

Reply from the authors

M. Imamura, K. Chayama, H. Aikata, 2012, Hepatology Research.

Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers

K. Awai, M. Imamura, K. Chayama, 2015, Journal of gastroenterology and hepatology.

Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

K. Awai, K. Chayama, H. Aikata, 2013, Journal of gastroenterology and hepatology.

Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.

M. Imamura, K. Chayama, M. Hijikata, 2021, Biochemical and biophysical research communications.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

M. Imamura, K. Chayama, M. Hijikata, 2019, The Journal of general virology.

Impact of viral eradication by direct‐acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus‐related compensated cirrhosis patients

M. Imamura, K. Chayama, D. Miki, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Comparison of hepatic arterial infusion chemotherapy between 5‐fluorouracil‐based continuous infusion chemotherapy and low‐dose cisplatin monotherapy for advanced hepatocellular carcinoma

K. Awai, M. Imamura, K. Chayama, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Role of 3‐D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

K. Awai, M. Imamura, K. Chayama, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Advanced liver fibrosis effects on the response to sofosbuvir‐based antiviral therapies for chronic hepatitis C

M. Imamura, K. Chayama, D. Miki, 2018, Journal of medical virology.

Real‐world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus‐related decompensated cirrhosis

M. Imamura, K. Chayama, D. Miki, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis

M. Imamura, K. Chayama, H. Aikata, 2019, Journal of Gastroenterology.

Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C

M. Imamura, K. Chayama, H. Aikata, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long‐term outcomes in 14 patients

K. Awai, M. Imamura, K. Chayama, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Long‐term outcome of patients with gastric varices treated by balloon‐occluded retrograde transvenous obliteration

K. Awai, M. Imamura, N. Hiraga, 2014, Journal of gastroenterology and hepatology.

Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability

M. Imamura, K. Chayama, H. Aikata, 2020, Clinical Journal of Gastroenterology.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy

M. Imamura, K. Chayama, H. Aikata, 2019, Clinical Journal of Gastroenterology.

Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices

K. Awai, M. Imamura, S. Oka, 2022, BMC gastroenterology.

Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis

M. Imamura, K. Chayama, Mio Tanaka, 2019, BMC Gastroenterology.

A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system

M. Imamura, K. Chayama, T. Wakita, 2021, IDCases.

[Hepatic artery pseudoaneurysm after endoscopic biliary stenting for pancreatic cancer].

K. Chayama, T. Ishigaki, Tamito Sasaki, 2014, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients

M. Imamura, K. Chayama, D. Miki, 2021, Journal of viral hepatitis.

Non‐invasive assessment of liver steatosis in non‐alcoholic fatty liver disease

M. Imamura, K. Chayama, K. Arihiro, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma

M. Imamura, K. Chayama, H. Nakagawa, 2020, Clinical and translational gastroenterology.

In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism

M. Imamura, K. Chayama, D. Miki, 2020, Molecular medicine reports.

Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.

K. Awai, M. Imamura, K. Chayama, 2020, European journal of radiology.

Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure

M. Imamura, H. Ohdan, S. Oka, 2023, Hepatology International.

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

M. Imamura, S. Oka, H. Aikata, 2023, BMC Gastroenterology.

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein

M. Imamura, S. Oka, D. Miki, 2023, Cancers.

Correlation between serum pro‐inflammatory cytokine levels and the prognosis of the patients with acute liver failure

M. Imamura, H. Ohdan, S. Oka, 2023, Journal of gastroenterology and hepatology.

Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma

M. Imamura, K. Chayama, H. Aikata, 2015, European Radiology.

HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL.

M. Imamura, K. Chayama, T. Fujita, 2022, Journal of Infectious Diseases.

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma

M. Imamura, H. Aikata, E. Murakami, 2022, Internal medicine.

Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt

K. Awai, M. Imamura, K. Chayama, 2019, Clinical journal of gastroenterology.

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment

K. Awai, M. Imamura, K. Chayama, 2023, Cancers.

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

M. Imamura, H. Aikata, E. Murakami, 2022, Liver Cancer.

The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib

M. Imamura, S. Oka, D. Miki, 2023, Oncology.

Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes

M. Imamura, S. Oka, D. Miki, 2023, European journal of gastroenterology & hepatology.

Long‐term outcome of patients with gastric varices treated by balloon‐occluded retrograde transvenous obliteration

K. Awai, M. Imamura, N. Hiraga, 2014, Journal of gastroenterology and hepatology.

Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy

K. Awai, K. Chayama, H. Aikata, 2013, Journal of gastroenterology and hepatology.

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

M. Imamura, K. Chayama, D. Miki, 2023, Communications medicine.

Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma

D. Miki, E. Murakami, T. Kawaoka, 2024, Cancer medicine.

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

D. Miki, S. Takaki, N. Mori, 2023, Cancers.

A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine.

D. Miki, E. Murakami, T. Kawaoka, 2024, Clinical journal of gastroenterology.